Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

47.98 +0.52 (+1.10%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
33 34 Next >
Hims & Hers Stock Crashed 26% Today. Here's What You Need to Know
Hims & Hers grew 95% in the fourth quarter of 2024, but investors were worried about GLP-1 growth. 
Via The Motley Fool
Traders are paying attention to the gapping stocks in Tuesday's session.
Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Hims & Hers Health Stock Is Plunging Tuesday: What's Going On?
Hims & Hers Health reported fourth-quarter revenue of $481.14 million, beating estimates of $470.31 million, according to Benzinga Pro. The company reported fourth-quarter earnings of 11 cents per... 
Via Benzinga
What's going on in today's pre-market session
Before the opening bell on Tuesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
Smart Money Is Betting Big In HIMS Options
Via Benzinga
Why Hims & Hers Health Stock Is Plummeting Today
Via The Motley Fool
Why Novo Nordisk Stock Popped on Friday
Via The Motley Fool
Tandem Diabetes (TNDM) Q4 Earnings: What To Expect
Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) will be reporting earnings tomorrow after the bell. Here’s what to expect. 
Via StockStory
Markets Mostly Dip Red Late In Regular Trading
Market indexes drooped in the final minutes of the normal trading day to start a new week, with all major indexes save the blue-chip Dow closing in the red, adding to Friday’s losses. 
Via Talk Markets
Topics Stocks Stocks / Equities
Hims & Hers Stock Sinks After-Hours As Weight-Loss Roadmap Gets Clouded — Retail Pounces On The Dip
On the earnings call, CEO Andrew Dudum acknowledged that the transition would be "inevitable" for patients currently on compounded semaglutide. 
Via Stocktwits
Topics Earnings
What's going on in today's after hours session
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Why the growth investor may take a look at NYSE:HIMS.
A fundamental analysis of (NYSE:HIMS): HIMS & HERS HEALTH INC (NYSE:HIMS) showing high EPS and FCF growth while beating expectations 
Via Chartmill
Why Hims & Hers Stock Dropped Today
Via The Motley Fool
Hims & Hers Health Stock Drops After Q4 Report: EPS In-Line, Revenues Beat
Hims & Hers Health reports its fourth-quarter results after Monday's closing bell. Here's a look at the key figures from the quarter. 
Via Benzinga
Hims & Hers Health (NYSE:HIMS) Beats Q4 Sales Targets But Stock Drops 16%
Telehealth company Hims & Hers Health (NYSE:HIMS) announced better-than-expected revenue in Q4 CY2024, with sales up 95.1% year on year to $481.1 million. On top of that, next quarter’s revenue... 
Via StockStory
Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results
From Hims & Hers
Via Business Wire
What To Expect When IBD 50's No. 2, Hims & Hers, Reports Amid The Semaglutide Battle
Hims & Hers Health is on deck to report its fourth-quarter earnings late Monday. Here's what to expect. 
Via Investor's Business Daily
Palantir Extends Losses, Microsoft Slides: What's Driving Markets Monday?
The major indices struggled to maintain early momentum on Monday, but appear to climbing back with the S&P 500 and Dow Jones both green in midday trading.  
Via Benzinga
Topics Stocks
Hims & Hers Retail Traders Eye Robust Post-Earnings Rebound Following Stock’s Worst Drop On Semaglutide Update
CEO Andrew Dudum acknowledged retail shareholders in a post on X, highlighting their deep research on the company and announcing plans to engage them directly on future earnings calls. 
Via Stocktwits
Hims & Hers Health (HIMS) To Report Earnings Tomorrow: Here Is What To Expect
Telehealth company Hims & Hers Health (NYSE:HIMS) will be reporting earnings tomorrow afternoon. Here’s what investors should know. 
Via StockStory
Earnings Scheduled For February 24, 2025
Via Benzinga
MarketBeat Week in Review – 02/17 - 02/21
Stocks were volatile this week as bad news gave investors a reason to sell; that volatility will continue next week with key retail earnings and inflation news 
Via MarketBeat
Topics Economy
Don't Call It A Stock Market Crash
A look at what today's price action means from a technical analysis standpoint, and what you can do to be prepared for whatever the stock market throws your way. 
Via Talk Markets
Topics ETFs Stocks / Equities
Top movers analysis one hour before the close of the markets on 2025-02-21: top gainers and losers in today's session.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Friday. Below you can find the top gainers and losers in today's session. 
Via Chartmill
Why Hims & Hers Health (HIMS) Shares Are Getting Obliterated Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 24% in the afternoon session after U.S. Food and Drug Administration (FDA) reported that the shortage of weight-loss drugs such as... 
Via StockStory
Topics Artificial Intelligence
Top movers in Friday's session
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
Stocks Firmly Lower As Consumer Sentiment Weakens
The Dow Jones Industrial Average is headed for another sharp triple-digit drop to end the week. 
Via Talk Markets
Topics Stocks Stocks / Equities
What's Going On With Hims & Hers Health Stock Today?
Hims & Hers Health acquired a peptide facility to strengthen its U.S. supply chain and meet demand for personalized treatments. Also, in another development, FDA resolves semaglutide injection... 
Via Benzinga
Topics Economy
Hims Stock Crashes After FDA Resolves Weight-Loss Drugs Shortage
The FDA said the shortages in Novo Nordisk's weight-loss drug has been resolved. 
Via Investor's Business Daily
Hims & Hers Acquires US-based Peptide Facility
From Hims & Hers
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 16
...
33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.